Neuphoria Therapeutics (NEUP) Non-Current Deferred Tax Liability (2020 - 2026)

Neuphoria Therapeutics (NEUP) has reported Non-Current Deferred Tax Liability for 7 consecutive years, with $390733.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 48.7% year-over-year to $390733.0 in Q1 2026; TTM through Mar 2026 was $390733.0, a 48.7% decrease from a year earlier, with the FY2025 full-year figure at $495113.0, down 48.62% from the prior year.
• Non-Current Deferred Tax Liability was $390733.0 for Q1 2026 at Neuphoria Therapeutics, down from $425527.0 in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $1.3 million in Q2 2022 and troughed at $390733.0 in Q1 2026.
• A 5-year average of $756589.6 and a median of $796530.5 in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability dropped 9.19% in 2022 and plunged 49.52% in 2025, its largest moves.
• Over 5 years, Non-Current Deferred Tax Liability stood at $1.3 million in 2022, then fell by 14.12% to $1.1 million in 2023, then declined by 23.81% to $842921.0 in 2024, then sank by 49.52% to $425527.0 in 2025, then slipped by 8.18% to $390733.0 in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $390733.0 (Q1 2026), $425527.0 (Q4 2025), and $460320.0 (Q3 2025), per Business Quant data.